Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ioflupane Clear all
Enrolling by invitation Phase 4 Interventional

DaTSCAN Imaging in Aging and Neurodegenerative Disease

NCT01453127
View directory record Official record
Conditions
Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
Interventions
I-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 4 Interventional Results available

A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms

NCT00382967
View directory record Official record
Conditions
Parkinsonian Syndromes
Interventions
DaTSCAN SPECT imaging
Procedure
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 5, 2026, 5:28 PM EDT
Active, not recruiting Phase 2 Interventional

Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

NCT04386317
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease, Symptomatic Parkinson Disease
Interventions
Terazosin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Active, not recruiting Phase 2 Interventional

Cardiac Changes in Early Parkinson's Disease: A Follow up Study

NCT04218968
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease
Interventions
Carvedilol
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Not listed No phase listed Observational

Validation of DaTscan for Detection of Parkinson Disease Related Disorders

NCT02138682
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders
Interventions
l-123 Ioflupane
Drug
Lead sponsor
Wisconsin Institute for Neurologic and Sleep Disorders S.C.
Industry
Eligibility
75 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational

Diagnosis of PD and PD Progression Using DWI

NCT02837172
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Diffusion Weighted Imaging (DWI)
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational

DatScan With Prototype Collimator

NCT02455219
View directory record Official record
Conditions
Parkinson Disease
Interventions
Prototype UHRSZ (UltraHigh Resolution Smart Zoom) Collimator
Device
Lead sponsor
University of Minnesota
Other
Eligibility
50 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational

Idiopathic Parkinson's Progression and Dopamine Transporter SPECT

NCT03531086
View directory record Official record
Conditions
Parkinson Disease
Interventions
Ioflupane I 123
Drug
Lead sponsor
Julie Gurwell
Other
Eligibility
40 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

NCT03675282
View directory record Official record
Conditions
Parkinson Disease, REM Sleep Behavior Disorder, Healthy
Interventions
(11C)PE2I, Ioflupane
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 100 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 5, 2026, 5:28 PM EDT
Withdrawn Phase 3 Interventional

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

NCT01950468
View directory record Official record
Conditions
Parkinson's Syndrome
Interventions
NAV5001, DaTscan
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects

NCT01788696
View directory record Official record
Conditions
Parkinson Disease
Interventions
Group A - Early Imaging, Group B - Delayed Imaging
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 5, 2026, 5:28 PM EDT
Active, not recruiting Phase 2 Interventional

Terazosin and Parkinson's Disease Extension Study

NCT05109364
View directory record Official record
Conditions
Symptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease
Interventions
Terazosin therapy
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Parkinsonism in Spinocerebellar Ataxia Type 6

NCT01934998
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 6
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational

Relationship Between Symptoms, Retinal Morphology, and the Nigrostriatal Dopamine System in Parkinson's Disease

NCT02443779
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
50 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational Results available

Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)

NCT01952678
View directory record Official record
Conditions
Essential Tremor, Parkinson's Disease
Interventions
DaTscan™ - Non-Caucasian Participants, DaTscan™ - Caucasian Participants
Other
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

NCT01141023
View directory record Official record
Conditions
Parkinson Disease
Interventions
DaTscan
Drug
Lead sponsor
Ken Marek, MD
Other
Eligibility
30 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
21
States / cities
Birmingham, Alabama • Sun City, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Systemic Synuclein Sampling Study (S4)

NCT02572713
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Biofluid samplings, Tissue samplings, DaTSCAN™
Procedure · Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
5
States / cities
Birmingham, Alabama • Scottsdale, Arizona • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 5, 2026, 5:28 PM EDT
Active, not recruiting No phase listed Observational

Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™

NCT04507139
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 5, 2026, 5:28 PM EDT
Recruiting No phase listed Observational

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

NCT03019757
View directory record Official record
Conditions
Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease
Interventions
DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, Clinical Assessment
Radiation · Genetic · Procedure + 1 more
Lead sponsor
Douglas Scharre
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 5, 2026, 5:28 PM EDT
Recruiting No phase listed Observational

The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

NCT03313011
View directory record Official record
Conditions
Apraxia of Speech, Non-fluent Aphasia, Primary Progressive Aphasia, Primary Progressive Nonfluent Aphasia
Interventions
Testing protocol for the study
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

NCT03587649
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Healthy Volunteers
Interventions
[18F]MNI-1126
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Parkinson's Disease Biomarker Program

NCT01767818
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years and older
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 5, 2026, 5:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Imaging Biomarkers of Delayed Sequelae in Trauma Brain Injury

NCT01516281
View directory record Official record
Conditions
Traumatic Brain Injury, Parkinson's Disease
Interventions
Not listed
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 5, 2026, 5:28 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

NCT03058965
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers, Progressive Supranuclear Palsy
Interventions
[18F]MNI-958, [18F]Florbetapir, DaTscan
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Sep 5, 2026, 5:28 PM EDT